Better Education on Glomerulonephritis: Improving Knowledge of IgA Nephropathy

To participate in this activity, please:

Log in Sign Up

Nephrology experts Jai Radhakrishnan, MD, and Dana Rizk, MD, delve into the complex disease of immunoglobulin A nephropathy (IgAN), addressing unmet treatment needs and novel frontiers of therapy. They discuss IgAN as a chronic disease, reviewing its pathophysiologic basis, morbidity and mortality including significant reductions in health-related quality of life, existing treatment options, and evolving new targeted therapies. The experts review treatment strategies and highlight case studies to depict key components of management and share their experience in conceptualizing this disease state with an eye towards improving long-term health outcomes.

This program is also available as a podcast. You may download it here: https://anchor.fm/GlomerulonephritisPodcast

Course Credit:

1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour

Dates:

Opens: 2022-07-31
Closes: 2023-09-30

Target Audience:

This activity was developed for nephrologists, pediatricians, general internists, surgeons who specialize in organ transplants, and other healthcare professionals who may be involved in the diagnosis and treatment of patients with IgAN.

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Accreditation Information

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 contact hour.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Heather Jimenez, MSN, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Andrea Sikora Newsome, PharmD (Medical Writer)

Consultant: AYMA Pharmaceuticals


Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Jai Radhakrishnan, MD

    Professor of Medicine
    Clinical Chief, Nephrology Division
    Columbia University Medical Center
    New York, New York

  • Dana Rizk, MD

    Professor of Medicine
    Division of Nephrology
    Medical Director
    Clinical Trials Administration Office
    University of Alabama at Birmingham
    Birmingham, Alabama

Learning Objectives

  • Describe the burden and the epidemiology of IgAN
  • Perform a comprehensive diagnosis of IgAN, identifying prognostic factors that may predict the progression of the disease
  • Explain the role and the possible consequences of proteinuria in patients with IgAN
  • Discuss the mechanism of action, safety and efficacy of new and emerging treatments for IgAN

Faculty Disclosures

Jai Radhakrishnan, MD

Advisory Board: Novartis, Travere Therapeutics
Consultant: Guidepoint, Sanofi Genzyme, Travere Therapeutics
Research Support:Travere Therapeutics


Dana Rizk, MD

Consultant: Angion Biomedica, Calliditas Therapeutics, Catalyst Biosciences, George Clinical, Novartis, Otsuka Pharmaceuticals
Founder and Co-owner: Reliant Glycosciences, LLC
National Leader: George Clinical
Research Support: Calliditas Therapeutics, Otsuka Pharmaceuticals, Pfizer, Reata Pharmaceuticals, Travere Therapeutics, Vera Therapeutics
Steering Committee: George Clinical, Novartis, Otsuka Pharmaceuticals